Taken together, these results suggest that SIRT1 overexpression is associated with ActD resistance, and that inhibiting SIRT1 with Rp1 could be of therapeutic benefit to overcome drug resistance in tumor cells. This evidence concerns the gene SIRT1 and neoplasm.